Overview
- From June 1, 2027, products with 50mg or less per recommended daily dose remain in general retail, 50–200mg require pharmacist advice, and more than 200mg will need a prescription.
- The final decision follows a review and public consultation that received 231 submissions, including 103 reports of severe or sometimes permanent effects.
- Regulators point to rising reports of peripheral neuropathy tied to long-term or cumulative B6 intake, with symptoms including tingling, burning or numbness in hands or feet.
- About 125 products on the Australian market are affected, with the timeline allowing businesses to update labels and manage stock.
- The recommended daily intake for healthy adults is about 1.3–1.7mg, deficiency is uncommon, and B6 appears in many combined supplements and fortified products that can compound exposure.